Introduction
Arterial ischemic stroke (AIS) and cerebral sinus venous thrombosis (CSVT) cause significant morbidity and mortality in children. The causes and clinical presentation in children are diverse and vastly different from adults. At the Children's Hospital of Philadelphia and other pediatric stroke centers, we employ a multidisciplinary approach for managing all children with cerebrovascular disorders. Affected children are evaluated by a team that includes neurologists with expertise in cerebrovascular disease, hematologists with expertise in coagulation disorders, neuroradiologists, rehabilitation experts, and intensivists. Patients are seen by an interactive team initially and reviewed at a weekly neurovascular conference. Specialized nurses working with the thrombosis clinic educate families on practical issues of anticoagulation. We believe that this approach optimizes patient outcomes. Here we review pediatric ischemic stroke and cerebral venous thrombosis, emphasizing the current clinical issues and illustrating the intersection between neurologic and hematologic factors as pathophysiologic determinants of these disorders. Accordingly, collaborations between these two subspecialties have led to an improvement in our understanding and care of affected children. In this review, we focus on recent advances that illustrate the importance of early recognition of pediatric cerebrovascular disease, comprehensive diagnostic evaluation, and prompt treatment. We highlight the importance of intersecting hematologic abnormalities and cerebrovascular disease in children and review the current published consensus-based treatment guidelines.
quadriparesis. Brain MRI and MR venogram (MRV) confirmed CSVT with subcortical white matter infarction (Fig. 1) . Lumbar puncture revealed elevated opening pressure (55 mmH 2 O), normal cerebrospinal fluid cell count, protein, and glucose. He received i.v. hydration and systemic anticoagulation with heparin. Laboratory studies showed Hgb 7.5 with iron deficiency, and a positive lupus anticoagulant, initially indicated by Childhood ischemic stroke and cerebral venous thrombosis Witmer and Ichord 21 prolonged partial thromboplastin time and confirmed by prolonged dilute Russel viper venom time (DRVVT). After starting heparin, mental status improved promptly, and the quadriparesis resolved steadily over 4 weeks. After 3 months of anticoagulation, repeat MRI/MRV showed recanalization of thrombosed sinuses. At follow-up, 2 years later, he appeared neurologically normal.
Physiology
Cerebral venous outflow involves a network of cortical and deep veins draining to the dural sinuses, and then to the jugular veins ( Fig. 1a and b) . CSVT obstructs venous outflow, leading to central venous and intracranial hypertension. At the time of diagnosis multiple venous sites of thrombotic obstruction are found, most frequently the transverse and superior sagittal sinuses [1] . Thrombosis progresses to venous infarction, often hemorrhagic, in 40-57% of children [2] [3] [4] . Diffuse cerebral edema with widespread infarction and hemorrhage can lead to herniation and death in the most severe cases, estimated at a frequency of 5-10%.
Epidemiology
Although CSVT affects all ages, neonates are disproportionately at risk, accounting for 27-61% of CSVT in children [2,3,5,6 ,7,8] . CSVT is estimated to affect 2.6/ 100 000 neonates and 0.35/100 000 children annually [3, 7] .
Clinical presentation
The clinical manifestations of CSVT are strongly influenced by age, thrombosis location, and the presence of a venous infarction. Symptoms are diverse and nonspecific, including most commonly the triad of headache, emesis, and depressed mental status. Seizures are common, especially in neonates. Mental status changes are variable, ranging from sleepiness and confusion to deep coma. Signs include obtundation or coma, papilledema, cranial nerve abnormalities (sixth nerve palsy), hemiparesis, quadriparesis, ataxia, and hyperreflexia. In neonatal CSVT, the most common signs and symptoms are lethargy, vomiting, a full fontanelle, and seizures [3] .
Cause
CSVT in children often results from multiple risk factors and inciting events. One or more risk factors, which vary with age can be identified in 71-100% children with CSVT [3] [4] [5] [7] [8] [9] . In newborns, acute systemic illness with dehydration and infection are the most common predisposing conditions. Among previously healthy children, acute head and neck infections, dehydration, and iron deficiency anemia are common. Chronic diseases associated with childhood CSVT include inflammatory bowel disease, cancer, autoimmune disorders, and chronic liver or renal disease. A detailed discussion of causes of CSVT can be found in published reviews [10 ,11 ] . [3, 4, 7, 9] compared with 15-29% in adults with CSVT [12, 13] . Two small pediatric case-control studies have examined the role of prothrombotic disorders in CSVT. Kenet et al. [9] found a prothrombotic condition in 42% of 46 children with CSVT, which was similar to the prevalence among 112 healthy controls. Heller et al. [7] compared prothrombotic risk factors in 149 pediatric patients with CSVT with 149 matched controls and found a significant association of CSVT with factor V Leiden and lipoprotein (a), protein C or protein S deficiencies. The prothrombin G20210A mutation was predictive of recurrence in a European cohort [14] . Conflicting results among existing studies indicate that more research is needed to better define the role of specific thrombophilias in pediatric CSVT. The current Pediatric Stroke consensus-based guidelines from the American Heart Association propose that children with CSVT may benefit from a thorough investigation to identify potential underlying thrombophilic tendencies [10 ] .
Diagnosis/imaging
Although computed tomography (CT) imaging is fast and convenient, this modality may miss the diagnosis of CSVT in up to 40% of cases [2, 3, [15] [16] [17] . CSVT is best identified using MRI with MRV [15, 17, 18] . CT venography is an alternative to MRI and MRV [15] , but has the disadvantage of significant radiation exposure. Ultrasound is convenient in infants with an open fontanel but is less sensitive than either CT or MRI [19] .
Therapy
There have been no clinical trials evaluating the treatment of CSVT in children. Current approaches are extrapolated from studies in adults, which support the safety and efficacy of anticoagulation [20, 21] . In a prospective cohort of 30 children with CSVT, 3/8 nonanticoagulated patients died versus 0/22 in the patients who received anticoagulation [22] , most typically heparin, either unfractionated or low molecular weight. There was no hemorrhage in the 12 patients who received low-molecular-weight heparin and only one clinically silent bleed out of the 10 patients who received heparin. Several other pediatric CSVT studies have also supported the safety of anticoagulation [3, 4, 7, 9] . A recent study from a multicenter European cohort found that recurrent CSVT was more likely in patients who did not receive anticoagulation for their first illness [14] .
Additional therapies for CSVT include thrombolysis or surgical thrombectomy. Among the few case reports of thrombolysis for CSVT [23] [24] [25] [26] , successful recanalization was achieved but with a high risk of intracranial hemorrhage. Current consensus-based guidelines suggest thrombolysis be reserved for patients who fail to improve, or who worsen, after a trial of anticoagulation. Detailed discussion of treatment for childhood CSVT is available in recently published guidelines, briefly summarized in Table 1 [10  ,11 ].
Recurrence
There are limited studies addressing the risk of recurrence in children with CSVT. The single-center cohort study of 160 pediatric patients with CSVT from Canada reported 13% recurrent venous thrombosis events, of which 63% were cerebral. Recently, in a large multicenter European cohort study there were 22 recurrent venous thrombotic events in 384 survivors of CSVT (6%) within a median of 6 months from the initial event (range 0.1-85) for a recurrence rate of 21.2/1000 person-years. Recurrent venous thrombosis occurred only in children whose first CSVT was diagnosed after 2 years of age. There were two deaths from CSVT at the time of recurrence. Risk factors for recurrence included age more than 2 years, failure to recanalize, the presence of the prothrombin gene mutation G20210A, and no administration of anticoagulation at the initial event.
Outcome Long-term sequelae from pediatric CSVT include chronic pseudotumor cerebri and cognitive and neurological deficits. In a recent European cohort study, 32% (12/37) of the pediatric CSVT survivors had evidence of chronic pseudotumor cerebri [4] . The prevalence of neurologic deficits reported in survivors of pediatric CSVT ranges from 25 to 38% [3] [4] [5] 9, 27] . In the Canadian cohort, predictors of poor neurological outcome included seizure at presentation in nonneonates and the presence of infarcts in all age groups [3] .
Arterial ischemic stroke
A 25-month-old male was recovering at home 4 days after uneventful surgery to repair an atrial septal defect, when he developed acute right hemiparesis. MRI disclosed an acute left middle cerebral artery (MCA) infarct with occlusion of distal left MCA branches ( Fig. 1e and f) . Echocardiogram showed no intracardiac thrombus or myocardial dysfunction, and laboratory studies revealed no prothrombotic states. He received low-molecular-weight heparin for 4 weeks, followed by aspirin, as well as intensive rehabilitation services. On follow-up 1 year later his examination and function were normal.
Physiology
Cerebral blood flow normally is tightly regulated to match metabolic activity under widely varying systemic fluctuations in blood pressure, blood glucose, O 2 , and CO 2 content. AIS occurs when flow-limiting arterial stenosis or thromboembolic occlusion causes irreversible tissue injury. The ischemic cascade involves reperfusion and flow redistribution, cellular and subcellular injury and
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Epidemiology
AIS is estimated to affect 1-13/100 000 children annually in North America and Europe [28, 29] , with about 30% involving neonates. AIS disproportionately affects males and African-Americans [6 ,28] . The basis for increased stroke risk related to gender, race/ethnicity, and geography is not understood, though both genetic and environmental factors likely contribute [30 ] .
Clinical presentation
Acute symptomatic neonatal AIS typically presents with depressed mental status and seizures. Delayed presentation of neonatal AIS (presumed perinatal ischemic stroke, PPIS) appears at 3-6 months of age as impaired motor development and hemiparesis. An excellent summary of the classification and description of clinical features of prenatal and perinatal-onset ischemic stroke is available [31] . AIS in children outside the neonatal period presents as sudden loss of neurologic function in a pattern consistent with an arterial territory. Typical signs and symptoms of anterior circulation stroke (carotid artery and its branches) include unilateral weakness and/or sensory loss involving face, arm, and leg; loss of speech or language comprehension (aphasia), often mistaken for confusion or oppositional behavior; visual field deficit; and focal seizures. Posterior circulation stroke (vertebrobasilar arteries) presents with a combination of diffuse signs and focal deficits referable to the brainstem and cerebellum, including acute ataxia, visual field loss, slurred speech, and eye movement deficits. Diffuse nonlocalizing symptoms, including severe headache, nausea, vomiting, and lethargy often dominate the chief complaint. Limited awareness of stroke, the difficulty of performing detailed neurologic examination in acutely ill children, and the need for MRI, which frequently requires sedation, all can delay definitive diagnosis, which, on average, occurs approximately 24 h after symptom onset [32, 33] .
Cause
Three major classes of disorders cause childhood AIS: hematologic and coagulation abnormalities, cardiac thromboembolism, and cervical or cerebral vasculopathy [34] . Causes of neonatal AIS include prothrombotic states, including maternal antiphospholipid antibody and placental disorders [35] . Thorough diagnostic evaluation reveals at least one risk factor in 75-80% of children with AIS. About half have a known underlying disease at the time of presentation (symptomatic stroke), including heart disease, hemoglobinopathy (most commonly sickle cell anemia with associated vasculopathy), head and neck trauma, infection, cancer, and autoimmune diseases that are frequently associated with antiphospholipid antibody.
Vasculopathies and prothrombotic conditions are the most common risk factors among previously healthy children with first AIS (cryptogenic stroke) [36] . Cerebral and cervical vasculopathies occur in 30-80% of children with AIS [36,37 ,38] . Multiple risk factors often coexist.
Prothrombotic abnormalities
Prothrombotic conditions affect 20-63% of newborns and children with AIS [39, 40] . Many children have multiple prothrombotic conditions, and many children with a known stroke risk factor such as heart disease also have a prothrombotic condition [41] . In a recent study of neonatal AIS, the combined incidence of prothrombotic conditions in mother and infant was found to be 78% [42] . The spectrum of identified prothrombotic conditions in AIS includes three general categories: heritable conditions, including protein C, protein S, or antithrombin deficiencies; factor V Leiden or prothrombin gene mutations; folate metabolism defects; lipoprotein (a) elevation; acquired conditions such as circulating prothrombotic antibodies (lupus anticoagulant/antiphospholipid antibody); and drug-induced or disease-related prothrombotic defects. In a meta-analysis of 3000 cases of childhood AIS and 9000 controls, Haywood et al. [43] found associations between first ischemic stroke and deficiencies in protein C, protein S and antithrombin; elevated plasma homocysteine, factor V Leiden and prothrombin mutations. A detailed discussion of prothrombotic conditions pertinent to childhood AIS can be found in the American Heart Association (AHA) Pediatric Stroke Treatment guidelines and the American College of Chest Physicians' Guidelines [10 ,11 ].
Whether to screen for prothrombotic conditions in pediatric CSVT or AIS is controversial, depending on the patient's age and clinical setting. However, identification of specific prothrombotic abnormalities can influence clinical care in numerous ways: severe anticoagulant deficiencies (protein C, S, or antithrombin) may be amenable to correction with fresh frozen plasma or recombinant factors; the presence of specific abnormalities can influence antithrombotic treatment decisions aimed at secondary stroke prevention; findings may alter management of comorbid conditions such as congenital heart disease; and families may be counseled on the risks for future thrombosis in the patient and his or her relatives.
Diagnosis/imaging
Evaluation of infants and children with suspected AIS rests on an accurate diagnosis, which requires adequate neuroimaging. Head CT is fast and widely available, but lacks sensitivity and specificity for ischemic injury. Brain MRI provides more reliable diagnosis of AIS in children, distinguishing it from stroke mimics such as demyelinating disease and tumor. MR angiography (MRA) of the head and neck should be obtained at the same time as MRI in any child with clinically suspected stroke, including newborns. CT angiogram is an alternative to MRA in situations where MR is inaccessible, but has the major disadvantage of high radiation exposure. Comprehensive evaluation is recommended for all infants and children with acute AIS, including vascular-imaging of the head and neck; cardiac -ECG and echocardiogram, possibly including bubble contrast; and hematologic -basic hematology profile, coagulation screens, and extended thrombophilia evaluation. The ideal thrombophilia evaluation is controversial and continually evolving as new information appears regarding the nature and significance of specific defects. Testing recommendations reflecting current evidence are summarized in the AHA Pediatric Stroke and Chest guidelines [10 ,11 ] .
Therapy
Therapy for AIS in childhood is guided by three principles ( Table 2) : limit the extent of injury acutely, promote recovery, and prevent recurrence There have been no clinical trials in childhood AIS other than the use of chronic transfusion to prevent stroke in children with sickle cell anemia. A key decision concerns the use of antithrombotic treatment, chosen from antiplatelet agents such as aspirin, systemic anticoagulation with a heparinoid, and thrombolytics. The use of thrombolysis (recombinant tissue plasminogen activator, tPA) is highly controversial in childhood AIS. There is strong consensus that tPA should not be used in neonatal stroke due to uncertainty regarding stroke onset. In older children and adolescents there is very limited data on safety and efficacy, and to date there is limited consensus among experts. The current AHA Guidelines suggest that tPA be used in children (preadolescents) only in the context of a clinical trial, and if considered for adolescents its use should adhere strictly to adult guidelines. Current practices with respect to antiplatelet and anticoagulation treatments vary widely among established pediatric stroke centers, reflecting uncertainty and lack of evidence-based guidelines [44] . Comprehensive reviews of this topic and consensus-based treatment recommendations are outlined in the AHA and Chest guidelines [10 ,11 ] .
Recurrence and outcome
Long-term sequelae affect 60% of children with AIS [35, [45] [46] [47] . Neurocognitive and psychosocial morbidities are the most significant. Predictors of long-term sequelae are incompletely understood and are influenced by infarct size and location, age of onset, and underlying cause. Reports of recurrence vary widely, ranging from 15 to 60% at 1-5 years. Children with chronic and progressive vasculopathies are at the highest risk of recurrence [48] [49] [50] . Prothrombotic risk factors increase recurrence risk [43, 51] . Current research efforts are focused on better understanding how systemic thrombophilias and arteriopathies interact biologically to influence AIS recurrence and long-term functional outcome [47, 52] .
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Conclusion
Important advances have been made in the understanding of childhood AIS and CSVT as a result of large, well investigated prospective cohort studies. These studies show that risk factors in children differ significantly from adults, and include prothrombotic disorders and cerebral vasculopathies. Continued progress in caring for children with AIS and CSVT will require greatly improved awareness of cerebrovascular disease among primary providers, who are most often the first point of contact. In particular, improved care will depend on more rapid and specific diagnosis using appropriate advanced neuroimaging technologies, comprehensive hematologic evaluation for inherited and acquired thrombophilias, and multidisciplinary approaches to treatment. Additional large cohort studies and clinical trials are greatly needed to develop sound evidence-based management guidelines.
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